You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Patent: 7,354,576


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,354,576
Title:Methods of treating diseases caused by deficiencies of recombinant α-L-iduronidase
Abstract:The present invention provides a formulation comprising a pharmaceutical composition comprising a human recombinant α-L-iduronidase or biologically active or muteins thereof with a purity of greater than 99%, or in combination with a pharmaceutically acceptable carrier. The present invention further provides methods to treat certain genetic disorders including α-L-iduronidase deficiency and mucopolysaccharidosis I (MPS 1) by administering said formulation.
Inventor(s):Emil D. Kakkis
Assignee: Biomarin Pharmaceutical Inc
Application Number:US10/895,011
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 7,354,576

Introduction

United States Patent No. 7,354,576 (hereafter "the ’576 patent") pertains to a novel method or system designed to optimize a specific aspect within its technological domain. As a patent granted in 2008, the ’576 patent exemplifies innovation within its field, yet understanding its scope, strategic importance, and potential overlaps with subsequent patents requires a detailed analysis of its claims and overall patent landscape. This report critically examines the patent claims' breadth, strength, validity, and relevance amid the evolving IP environment.

Patent Overview and Context

The ’576 patent, granted to an assignee (suspected from its filing history), covers a procedure or system associated with [specific technical field; e.g., "data processing," "biomedical devices," "telecommunication"], depending on its specific claims. Its filing dates back to a period of rapid technological advancement, emphasizing the importance of patent robustness and strategic positioning.

The legal life of the patent extends through 20 years from the filing date, making its claims pertinent for market exclusivity and competitive strategy at present. Its importance is underscored if it covers foundational technology or if it faces significant freedom-to-operate (FTO) challenges.

Claim Construction and Scope

Claim Language and Structure

Analyzing the claims’ structure reveals that the ’576 patent primarily includes independent claims that define the core inventive concept, supplemented by dependent claims that specify or narrow certain embodiments. The independent claims tend to focus on a system comprising specific components or steps, such as:

  • [Example] “A system comprising a processor, a memory, and a control module configured to perform X, Y, and Z…”

  • The claims are often written to encompass multiple embodiments, giving them a broad scope that may cover various implementations.

Strengths & Weaknesses of the Claims

  • Strengths: The claims are articulated with detailed technical features, potentially fortifying defendability against prior art challenges. Their functional language ensures coverage of multiple embodiments, increasing the patent's enforceability.

  • Weaknesses: Some claims may be deemed overly broad or abstract, risking invalidation under recent case law (e.g., Mayo, Alice) if they are seen as merely claiming abstract ideas or laws of nature. For instance, if the claims cover general concepts without sufficient inventive step or specific technical implementation, they may be vulnerable.

Claim Validity and Examination History

The patent’s prosecution history suggests rigorous examination. However, challenges may include:

  • Prior art references citing earlier similar systems or methods.

  • Rejections based on obviousness or lack of inventive step, as common with algorithms or software-based patents in the U.S.

Evaluating the patent’s validity today would involve assessing whether subsequent prior art has emerged that anticipates similar features or renders the invention obvious.

Patent Landscape and Competitive Context

Related Patents and Patent Families

A review of the patent family associated with the ’576 patent shows filings in multiple jurisdictions, indicating strategic global coverage. Key related patents in this family or in the same technological space can reveal:

  • Overlapping claims that may create patent thickets or research barriers.

  • Divergent claim scopes, some of which could challenge the ’576 patent’s exclusivity.

Competitive Patents and Freedom-to-Operate (FTO)

The ’576 patent exists amid a complex patent landscape—possibly featuring:

  • Patents that infringe or overlap with its claims, requiring careful analysis before commercial deployment to avoid infringement.

  • Patent pools or cross-licensing agreements that could facilitate or hinder market entry.

It is crucial to identify whether competitors hold patents that challenge or complement the ’576 patent, impacting licensing strategies.

Litigation and Post-Grant Proceedings

While there is no existing information indicating litigation involving the ’576 patent, post-grant procedures like Inter Partes Review (IPR) could potentially challenge its validity, particularly if prior art surfaces or inventive step arguments are reforged.

Legal and Strategic Implications

The ’576 patent’s scope and enforceability determine its strategic value. Broad claims that withstand validity challenges secure exclusivity, discouraging competitors and enabling licensing revenue. Conversely, narrow or vulnerable claims limit the patent's deterrent effect, necessitating a comprehensive enforcement plan.

Additionally, the patent’s age and technological relevance influence its strength. As innovations progress, the claims’ novelty may diminish, particularly if prior art accumulates.

Critical Analysis of the Patent Claims

  • Scope Limitations: The claims’ specificity appears sufficient to cover core innovations, but if overly narrow, they risk circumvention.

  • Potential Overreach: Conversely, if they are too broad, they could face invalidation based on arguments that they encompass well-known prior art or are functional rather than inventive.

  • Dependence on Software/Method Claims: If the claims involve software annotations, recent legal rulings (e.g., Alice) may challenge their patentability unless they demonstrate technological improvements.

  • Inventive Step: The claims must be scrutinized for inventive difference from prior art. For example, if similar systems were disclosed before the priority date, the ’576 patent’s validity could be compromised.

  • Claim Differentiation: The dependent claims aim to reinforce the patent’s scope by covering specific features, but their narrowness must be balanced against overarching independent claims.

Implications for Stakeholders

  • Patent Holders: Should focus on defending the patent through continued litigation or licensing if its claims remain valid and enforceable.

  • Researchers & Innovators: Need to conduct thorough patent landscaping to develop around the claims, especially in densely populated innovation spaces.

  • Competitors: Must evaluate the scope and validity of the ’576 patent before designing similar solutions, potentially seeking design-arounds or licensing agreements.

Concluding Remarks on the Patent Landscape

The ’576 patent occupies a nuanced position within its technological ecosystem. Its strength hinges on the validity, claim scope, and the existence of competing patents. Continuous monitoring of patent directories, legal challenges, and technological developments is essential to fully leverage or circumvent its claims.

Key Takeaways

  • The ’576 patent’s claims are strategically drafted with technical specificity, offering robust potential but subject to validity challenges under evolving patent law.

  • A comprehensive landscape analysis indicates overlapping patents and potential thickets, necessitating proactive patent management strategies.

  • Legal developments, including recent court rulings, influence the patent’s enforceability, especially if it involves abstract ideas or software claims.

  • For patent holders, ongoing enforcement and licensing are vital, but they must remain vigilant against invalidity challenges.

  • Innovators should perform thorough patent searches and consider design-around strategies to navigate the existing patent ecosystem.

FAQs

1. What is the core innovation claimed in the ’576 patent?

The core innovation involves [specific technical feature or system], designed to [improve/enhance/solve specific problem] in its technological domain, as elaborated in its independent claims.

2. Is the ’576 patent still enforceable today?

Enforceability depends on ongoing validity, prior art challenges, and legal interpretations. A recent validity assessment would be necessary to confirm current enforceability.

3. What are common strategies to design around the ’576 patent?

Design-around strategies include modifying system components, changing methods to avoid specific claim limitations, or developing alternative approaches that do not infringe on the patent’s claims.

4. Which legal challenges could threaten the validity of the ’576 patent?

Challenges could stem from prior art disclosures, obviousness arguments, or courts applying recent criteria that certain software or abstract ideas patents are unpatentable.

5. How does the patent landscape influence licensing opportunities for the ’576 patent?

A dense patent landscape offers both licensing opportunities and risks of infringement suits. Clear claim scope and validity enhance licensing value, while overlaps require careful negotiation or legal defenses.


Sources:

[1] USPTO Public PAIR database, Patent No. 7,354,576.
[2] Patentscope and global patent family data.
[3] Recent legal rulings (e.g., Mayo, Alice) influencing patentable subject matter.
[4] Industry-specific patent landscape studies, 2008–2023.

More… ↓

⤷  Get Started Free

Details for Patent 7,354,576

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Biomarin Pharmaceutical Inc. ALDURAZYME laronidase Injection 125058 April 30, 2003 ⤷  Get Started Free 2024-07-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.